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ABSTRACT 
Katie Rose Hirsch: Metabolic characterization of overweight and obese adults 
(Under the direction of Abbie E. Smith-Ryan) 
 
Obesity is associated with diseases such as metabolic syndrome, but not all obese 
individuals have traditional markers of dysfunction like insulin resistance and dyslipidemia.  To 
characterize metabolic health in 49 overweight and obese adults, body composition (fat mass 
[FM], lean mass [LM], percent body fat [%fat]), was calculated using a 4-compartment model; 
visceral adipose tissue (VAT) was quantified using B-mode ultrasound.  Resting metabolic rate 
(RMR), respiratory exchange ratio (at rest and during exercise), fasting lipids, insulin, and leptin 
were also analyzed.  Fat mass, %fat, and VAT correlated with insulin and leptin (r=0.369-0.829; 
p<0.05); FM was not correlated with lipids (p>0.05).  Higher RMR was associated with LM 
(r=0.900, p<0.001).  When evaluating body composition and metabolism in addition to 
traditional metabolic syndrome criteria, individuals with disease risk increased from 29% to 
80%.  Lean mass, VAT, RMR, and hormones may be indicators of metabolic dysfunction in the 
absence of traditional risk factors. 
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CHAPTER I 
INTRODUCTION 
 
 Metabolic syndrome is a chronic disease characterized by the presence of multiple risk 
factors that indicate metabolic dysfunction [1].  Many of these risk factors, such as insulin 
resistance and dyslipidemia, are also associated with an increased risk for the development of  
cardiovascular disease (CVD)  and type 2 diabetes [1, 2].  Currently, over two-thirds of adults in 
the United States are considered overweight or obese [3].  Of these individuals, an estimated 
50% of overweight and about 70% of obese adults have at least two metabolic risk factors [4] 
placing a majority of the population at an increased risk for chronic diseases [4, 5].  The 
associations between body fat and disease risk has resulted in decades of research with a primary 
focus on the reduction of body fat.  While short-term success has been achieved, mainly through 
diet and exercise interventions, long-term maintenance is not as successful.  About one third of 
adults who lose weight will have regained all of their weight after one year [6], with most 
regaining after five years [7].  The inability to maintain weight loss may suggest that other 
factors beyond fat mass (FM) are influencing metabolic health.  Further, while metabolic 
syndrome is strongly associated with obesity [8], there are a number of obese individuals who 
are considered metabolically healthy exhibiting just one cardiometabolic risk factor [9].  Despite 
having normal blood lipid profiles (normal high-density lipoproteins; low plasma triglycerides) 
and being insulin sensitive [10, 11], the presence of excess body fat may be a sign of underlying 
metabolic dysfunction that could develop into metabolic syndrome.  Factors such as visceral 
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adipose tissue (VAT), lean mass (LM), resting metabolic rate (RMR), fuel utilization at rest and 
during exercise, and hormonal profiles, may give a more complete picture of metabolic health in 
overweight and obese adults, improving approaches to early identification of metabolic 
dysfunction. 
Regional distribution of body fat, or where an individual stores their body fat, may be 
more highly associated with an increased risk of metabolic dysfunction, than the overall presence 
of excess body fat [10, 12].  Previous studies have shown that high VAT, fat located within the 
abdominal cavity around the organs, is more significantly related to insulin resistance as opposed 
to subcutaneous adipose tissue [12, 13].  In a study by Brochu et al. (2001), insulin resistance 
was more prevalent in obese women with greater VAT when matched for total body and 
abdominal subcutaneous fat.  Further, in the absence of excess body fat, normal weight 
individuals with increased VAT, also demonstrate a greater prevalence of insulin resistance [12].  
The strong association between VAT and insulin resistance has resulted in VAT being regarded 
as more harmful to metabolic health.  However subcutaneous fat may still have a significant 
impact on metabolic regulation.  Subcutaneous adipose tissue not only serves as a storage 
location for excess energy, but it also serves as an important endocrine organ [14].  Previously 
shown to be related to the production and balance of metabolic hormones, excess subcutaneous 
fat may lead to hormonal imbalances that promote metabolic dysfunction [15].  Leptin 
specifically, is more strongly associated with subcutaneous and overall body fat than VAT, [12, 
16, 17].  Leptin is a hormone secreted by adipose tissue as a signal of chronic energy stores (fat 
mass) that serves as a regulator of energy balance [18].  Since obese individuals have excess 
body fat, high concentrations of leptin should decrease energy intake and increase energy 
expenditure, promoting a return to normal weight.  However, obese individuals with high leptin 
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levels often have no associated changes in FM and energy expenditure, potentially symbolizing 
leptin resistance [18].  Despite its potential physiological function, the role of leptin in energy 
expenditure is not completely understood.  There is some recent speculation that there may be an 
inhibitory relationship between insulin and leptin, with high insulin levels blocking the leptin 
signal and promoting energy storage [19].  It has also been theorized that high leptin levels may 
increase RMR, but this relationship has not yet been observed in humans [20, 21].  Other 
hormones that have associations with fat distribution are estrogen and cortisol.  Estrogen has 
been shown to influence fat distribution by increasing gynoid and subcutaneous fat accumulation 
[12, 15, 22].  Low estrogen levels in obese women are associated with increases in VAT, while 
high levels estrogen in obese men may have similar consequences [23-25].  In contrast, cortisol, 
commonly associated with an elevated stress response, has been shown to be associated with 
greater body fat and VAT, which over time could lead to changes in substrate metabolism and 
insulin resistance [26-28].  Evaluation of hormonal profiles in relation to fat distribution may be 
an important indicator of metabolic health in the absence of traditional markers.  Fat distribution 
is typically evaluated in clinical settings using waist circumference measurements, which do not 
differentiate between visceral and subcutaneous distribution.  Recently validated techniques such 
as ultrasonography (US) may be a feasible option for clinical evaluation of abdominal fat 
distribution, but further evaluation of its clinical utility is needed. 
In contrast to the negative relationship between total and regional fat distribution and 
metabolic health, LM is typically beneficial to metabolic health.  As the major location for 
glucose storage and metabolism, LM is commonly overlooked in the context of obesity and 
metabolic disease.  Lean mass has a significant impact on energy expenditure, accounting for up 
to 63% of the inter-individual variability in RMR [29].  Losses in LM are associated with 
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decreases in RMR, insulin resistance, and poor functionality [30], all of which are associated 
with weight gain.  Lean mass may also be important in fuel utilization and maintaining metabolic 
flexibility.  At rest, a healthy individual typically derives a greater portion of their energy from 
fat oxidation.  During exercise or after eating a meal with a reasonable amount of carbohydrates, 
carbohydrate oxidation increases to match the greater energy demand.  Impaired fat oxidation at 
rest and chronic reliance on carbohydrate oxidation is a sign of metabolic dysfunction and is 
considered to be a risk factor for weight gain [28, 31].  The metabolic consequences of low LM, 
and conversely the potential benefits of greater LM, supports the importance of evaluating LM in 
obese populations. 
In order to gain a better understanding of metabolic health in overweight and obese 
adults, better characterization of this population is necessary.  Insulin resistance and dyslipidemia 
are an indication of metabolic dysfunction, but in their absence, other factors may be a sign of a 
developing dysfunction.  Better characterization of fat distribution and its relation to adipose 
related hormones, like insulin, leptin, estrogen, and cortisol may give further insights into the 
metabolic consequences of hormonal imbalance.  Differences in fat distribution, especially 
between males and females, may have different effects on hormonal balance and metabolic 
regulation, which could serve as a risk factor for development of metabolic syndrome.  Further, 
consideration of LM, RMR, and fuel utilization determined from respiratory exchange ratio 
(RER) at rest (RERrest) and during steady-state exercise (RERbike) in relation to FM, percent body 
fat (%fat) and hormonal profiles may influence future approaches to obesity interventions. 
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Purpose 
1. The primary purpose of this study was to characterize metabolic health in overweight and 
obese adults by evaluating body composition (FM, LM, %fat, VAT), RMR, RERrest, 
RERbike, glucose, lipids, and hormones (insulin, leptin, estrogen, cortisol). 
a. A component of this purpose assessed the relationships between these variables, 
as well as differences between overweight and obese. 
2. A secondary purpose of this study was to evaluate sex differences between body 
composition (FM, LM, %fat, VAT), RMR, RERrest, RERbike, glucose, lipids, and 
hormones (insulin, leptin, estrogen, cortisol). 
a. A component of this purpose assessed sex differences, while also accounting for 
dietary intake and LM. 
3. A tertiary purpose of this study was to assess how well variances in non-standard factors 
of metabolic health (FM, LM, %fat, VAT, RMR, RERrest, RERbike, ΔRER), were 
explained by standard clinical measures of metabolic health (glucose, lipids, insulin, 
leptin, estrogen, cortisol). 
a. A component of this purpose assessed how well variances in non-standard factors 
of metabolic health were explained by standard clinical measures of metabolic 
health, including VAT as a potentially feasible clinical factor. 
Research Questions 
1. Is there a relationship between total and regional body composition, RMR, RERrest, 
RERbike, glucose, lipids, and hormones in overweight and obese adults?  
2. Is there a relationship between leptin, RMR and RERrest, RERbike? 
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3. Are there differences in total and regional body composition, RMR, RERrest, RERbike, 
glucose, lipids, and hormones between overweight and obese adults? 
4. Are there differences in RMR, RERrest, RERbike, glucose, lipids, and hormones between 
men and women, when accounting for dietary intake and body composition? 
5. Will variances in total and regional body composition, RMR, RERrest, RERbike, and 
ΔRER be explained by blood and hormonal markers of metabolic health? 
6. Are there differences in relationships between VAT and markers of metabolic health 
when measured via B-mode US or dual-energy x-ray absorptiometry (DEXA)? 
Research Hypothesis 
1. Fat mass, %fat, and VAT would be positively correlated and LM would be negatively 
correlated with compromised lipid levels (plasma triglycerides, HDL) and hormonal 
profiles (insulin, leptin, estrogen, cortisol). 
2. Fat mass, %fat, and VAT would be negatively correlated and LM would be positively 
correlated with RMR; FM, %fat, and VAT would be positively correlated and LM would 
be negatively correlated with RER. 
a. There would be a significant relationship between leptin levels, RMR, RERrest, 
and RERbike. 
3. There would be differences in RMR, RERrest, RERbike, glucose, lipids, between men and 
women, after accounting for dietary intake and body composition. There would be no 
differences between men and women in RMR when controlled for differences in body 
mass and LM, while women will have a lower RER than men.  Men would have higher 
fasting insulin concentrations, while women would have higher leptin and estrogen 
levels.  There would be no sex differences in cortisol levels.  
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Delimitations 
1. Subjects were between the ages of 18-55 years. 
2. Healthy men and pre-menopausal women were recruited. 
3. Subjects had a BMI of 25-52 kg∙m-2 and/or body fat percentage between 25-53%. 
4. Subject were not taking any dietary supplements or using a meal replacement. 
5. Subjects were not consuming a low-carbohydrate or ketogenic diet. 
6. Body composition was measured by 4-compartment model. 
7. Visceral adipose tissue was measured by B-mode US and DEXA. 
8. Insulin, leptin, and lipid levels were measured from a blood draw. 
9. Estradiol and cortisol concentrations were measured from a saliva sample. 
10. Indirect calorimetry was used to measure RMR, RERrest and RERbike. 
Limitations 
1. Visceral adipose tissue was measured using US, rather than computed tomography (CT) 
scan which is considered the gold standard. 
2. Indirect calorimetry was used to measure RMR, RERrest and RERbike, rather than direct 
calorimetry which is considered the gold standard. 
3. A cross-sectional design will characterize overweight and obese individuals at a single 
point in time, but does not allow for evaluation of potential risk factors over time.   
Assumptions 
Theoretical 
1. Subjects accurately reported health and exercise history information. 
2. Subjects provided accurate dietary intake information on nutrition logs. 
3. Subjects followed pre-testing exercise and dietary guidelines. 
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Statistical 
1. The population from which the sample was taken was normally distributed. 
2. The sample variability was equal. 
Definition of Terms 
Overweight – having a BMI of 25-29.9 kg·m-2  
Obese – having a BMI of 30-45 kg·m-2  
Fat mass (FM) – all extractable lipids that can be extracted from adipose and other tissues [32]. 
Lean mass (LM) – all residual lipid-free chemicals and tissues including water, muscle, 
connective tissue, organs, and bone [32]. 
Percent body fat (%fat) – fat mass expressed as a percentage of total body weight  
Total body volume [33]  – estimate of body size and density using air displacement [32]. 
Total body water (TBW) – a measure of the intracellular and extracellular fluid compartments of 
the body estimated using bioelectrical impedance spectroscopy [32]. 
Total body bone mineral density (Mo) – a measure of the bone mineral content of the body 
estimated using dual-energy x-ray absorptiometry [32]. 
Body Mass (BM) – body weight measured in kilograms [32]. 
Visceral adipose tissue (VAT) – intra-abdominal adipose tissue; quantified as a measurement of 
adipose tissue that exists between the interior border of the rectus abdominis and the 
posterior wall of the aorta [34-36]. 
Estradiol – a female sex hormone; measured using a salivary estradiol ELISA kit (pg/mL) 
Cortisol – glucocorticoid involved with maintaining blood glucose; free cortisol concentrations 
measured using a salivary cortisol ELISA kit (µg/dL). 
Blood glucose – measure of glucose concentrations in the blood (mg/dL) 
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Total cholesterol – measure of all cholesterol in the blood (mg/dL) 
Triglycerides – measure of fats in the blood (mg/dL) 
HDL – high density lipoproteins in the blood (mg/dL) 
LDL – low density lipoproteins in the blood (mg/dL) 
LMI – Lean mass index (LM[kg]/m2) 
Insulin – hormone promoting glucose uptake from the blood (uIU/mL)  
Leptin – adipose hormone signaling energy stores (ng/mL). 
Maximum Heart Rate (HRmax) – estimate of the greatest number of beats per minute that can be 
achieved by the heart (220-age) 
Heart Rate Reserve (HRR) – difference between maximum heart rate and resting heart rate used 
to prescribe exercise intensities; Karvonen formula HRR = [HRmax - HRrest] x %intensity 
+ HRrest 
Resting metabolic rate (RMR) – energy expended while at rest in a supine position, but still 
awake, as measured using indirect calorimetry (kcal/day) [37]. 
Respiratory exchange ratio (RER) – a measure of fuel utilization that uses a ratio of carbon 
dioxide expired to volume of oxygen consumed to estimate the contribution of fat and 
carbohydrate to energy expenditure at rest and during submaximal exercise.  
Respiratory exchange ratio at rest (RERrest) - Respiratory exchange ratio measured during a 
resting state. 
Respiratory exchange ratio during steady-state (RERbike)  – Respiratory exchange ratio during a 
steady-state cycle ergometer bout. 
Change in respiratory exchange ratio during steady-state (ΔRER) – Change in respiratory 
exchange ratio; difference between RERbike and RERrest 
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Significance of Study 
This study evaluated the relationships between body composition, RMR, RER, glucose, 
lipids, and hormones in order to better characterize overweight and obese individuals.  In order 
to gain a better understanding of factors that place these individuals at an increased risk of 
metabolic syndrome, a more comprehensive analysis of body composition, beyond the use of 
BMI, should be used to categorize and assess overweight and obese individuals. This study used 
a 4-compartment (4C) model and US in order to assess FM, LM, %fat, and VAT.  A 4C model 
incorporates measures from multiple methods of assessing body composition, for a more 
accurate estimation, while US may be a feasible option for a more direct measures of VAT.  
Body composition, RMR, RER, and hormones have previously been assessed separately in obese 
populations, but have not been assessed together, which may provide insight into relationships 
between factors.  This study also attempted to gain a better understanding of the relationships 
between leptin, body composition, RMR, and RER.  Finally, evaluating RMR and RER in 
relation to body composition, glucose, lipids, and hormones, may provide information that can 
be used to promote long term metabolic health. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
Introduction 
There is a well-established association between obesity and an increased risk of chronic 
diseases, such as cardiovascular disease, type II diabetes, and metabolic syndrome [4, 5].  
Metabolic syndrome is a disease defined by the presence of three or more risk factors related to 
an increased risk of cardiovascular disease, which include: abdominal obesity (waist 
circumference: men>102 cm; women>88 cm), elevated triglycerides (≥150 mg/dl), low HDL 
cholesterol (men<40 mg/dl; women<50 mg/dl), high blood pressure (≥ 130/85 mm/Hg), and 
elevated glucose (≥110 mg/dl) [1].  Obese individuals (BMI ≥ 30 kg/m2) have been shown to 
have the highest prevalence of metabolic syndrome [8, 13], likely related to complications 
associated with high amounts of adiposity.  Increased FM and a higher %fat is associated with 
decreased insulin sensitivity [9, 12, 38], and poor lipid profiles, primarily high plasma 
triglycerides and low HDL [13].  Despite short term success at weight loss, 33.5% of individuals 
will regain weight after only one year [6].  The prevalence of obesity and the inability to 
maintain long term weight loss may be an indication of metabolic dysfunction beyond the 
presence of body fat.  Comprehensive characterization of the body composition, hormonal 
profile, and metabolic rate may provide greater insight into metabolic health of overweight and 
obese individuals. 
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Body Composition 
 Many studies use insulin sensitivity as the primary defining factor of metabolic health 
due to the association of insulin resistance with the development of type 2 diabetes, 
hypertension, and cardiovascular disease [5, 39].  Excess adiposity, especially in the abdominal 
region, has been shown to be associated with insulin resistance and poor lipid profiles.  In a 
study by Brochu et al (2001), obese postmenopausal women who were insulin resistant had 
significantly more VAT than women who were insulin sensitive when matched for whole body 
FM and abdominal subcutaneous fat.  In the same study, VAT was also found to be an 
independent predictor of both insulin sensitivity and fasting plasma triglyceride concentrations.  
Other studies have reported similar findings with higher amounts of VAT being associated with 
insulin resistance and poor lipid profiles [11].  In contrast, other studies have demonstrated 
associations with subcutaneous fat [40].  Discrepancies may be the result of population and sex 
differences, as well as the method used for evaluation of body composition.  Computed 
topomyography (CT) is considered the criterion method for assessing VAT [41]; however, CT 
scans are expensive, time consuming, and are not always a feasible option at the clinical level 
when assessing large populations.  Waist circumference and waist-to-hip ratio are often used to 
assess abdominal obesity, due to ease and portability, yet provide a more global assessment of fat 
distribution.  Recently, US has been recognized as a valid measure of VAT compared to CT [42, 
43].   US may provide a more affordable and feasible way to assess VAT.  Due to the portability, 
US may allow for a more accurate assessment of VAT in a variety of settings.  As a result of 
potential impacts and feasibility, more research utilizing US for determining associations 
between fat distribution and other components of metabolic health may be valuable.  
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There is a growing body of research focusing on the hormonal profile of obesity and 
metabolic dysfunction.  Hormones such as adiponectin, resistin, leptin, and ghrelin are important 
hormones involved in the regulation of appetite and energy balance [18, 44].  Leptin in particular 
is produced by adipose tissue as an indication of long term energy stores (body fat).  While 
details of the leptin mechanism are not completely understood, high levels of circulating leptin 
activates receptors on the hypothalamus.  This triggers an endocrine response that promotes 
metabolic rate and initiates satiety.  In contrast, low leptin levels signal a lack of energy or 
starvation, triggering an endocrine response that promotes energy storage [18, 44].  Disruptions 
to this feedback loop, have been shown to result in increased FM and appetite in obese 
individuals, attributed to leptin deficiency or leptin resistance.  While leptin levels are positively 
correlated with BMI and %fat [16, 21, 45, 46], a wide range of concentrations have been 
reported for obese individuals [46, 47].  Many obese individuals with high leptin levels, still have 
normal to high food intake and leptin treatments for deficiency have had limited effects on 
weight loss, indicating leptin resistance [19].   While the mechanism for leptin resistance is 
currently unknown, potential influences of fat distribution and interactions with other hormones 
are potential factors.  Despite the general positive association between leptin and %fat, it is 
unclear whether leptin has stronger associations with VAT or subcutaneous fat [16, 46], though 
there is some suggestion of a greater association with subcutaneous fat [12, 16, 17].  Leptin and 
insulin have been shown to circulate in the bloodstream in proportion to FM [19].  Elevated 
insulin concentrations, as would be observed in insulin resistant type 2 diabetics or those with 
metabolic syndrome, may have inhibitory effects on leptin with competing signals to the 
hypothalamus [19].  Estrogen may also have interactions with leptin production as women are 
regularly reported as having higher leptin levels compared to men [12, 17, 21, 46].  Estrogen is 
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also thought to influence fat distribution with estrogen concentrations showing greater 
associations with subcutaneous fat accumulation in women [12, 48].  Like estrogen, elevated 
cortisol levels may promote VAT accumulation which could lead to insulin resistance [26, 27].  
Cortisol is a stress related hormone that helps maintain blood glucose levels.  Stressors include 
diet, exercise, environmental stress, emotional stress, and sleep deprivation [26].  High cortisol 
levels have been observed in association with greater amounts of VAT [27], but it is still unclear 
if elevated cortisol promotes VAT accumulation or vice versa [49]. 
An additional component of body composition that is commonly overlooked in the 
context of obesity is LM.  Lean mass is a major site for insulin binding and subsequent glucose 
uptake.  Increased FM or intramuscular fat infiltration can interfere with glucose uptake, either 
by decreasing insulin sensitivity or by inhibiting glucose oxidation [50].  Over time, insulin 
resistance may develop, leading to the development of metabolic syndrome and type 2 diabetes 
[30].  Loss of LM itself decreases the location for insulin binding which can exacerbate diseases 
such as cardiac cechaxia, sarcopenia, osteoporosis, and type 2 diabetes [30].  Lean mass is also a 
major contributing factor to RMR, the largest component of energy expenditure [29].  Decreases 
in LM are associated with decreases in RMR, which can lead to energy imbalance and weight 
gain [29].  Further, a condition known as sarcopenic obesity is characterized by low LM and a 
poor strength-to-body size ratio [51].  Low LM and poor strength directly impact functionality, 
decreasing overall quality of life and the ability to perform activities of daily living [52].  Despite 
its important physiological role in insulin sensitivity, energy balance, and functionality, LM is 
often not quantified in overweight and obese populations.  Most research is focused on the 
consequences of fat accumulation, but effectively losing FM has proven to be difficult, as 
observed in the continued prevalence of obesity.  Lean mass is more metabolically active than 
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FM making it more adaptable.  Increasing LM may be a more effective approach to changing 
body composition that would also lead to improvements in other areas of metabolic health, such 
as hormonal profiles and energy expenditure.  The characterization of whole body and regional 
LM in overweight and obese populations in relation to specific hormones is needed in order to 
better understand metabolic health in this population.  
Energy Expenditure 
In its most basic definition, obesity is the result of energy imbalance.  When energy 
intake exceeds energy expenditure, weight gain typically ensues [53].  Energy expenditure has 
four components: RMR, thermic effect of food, non-exercise adaptive thermogenesis, and 
physical activity energy expenditure [54].  Alterations in body composition and hormonal profile 
may cause changes in RMR that could promote weight gain and resistance to weight loss. 
Resting metabolic rate accounts for the largest caloric requirements of energy 
expenditure [55].  A lower RMR is often associated with weight gain [53] and is highly 
influenced by the presence of LM [29, 55].  Johnstone et al. (2005) reported that LM accounted 
for 63% of between-subject variance in RMR.  Of the remaining 36%, about 9% was explained 
by differences in FM, age, and analytic error, and 27% was unexplained.  Hormonal factors, such 
as leptin, may explain some of this variation.  Chronically, circulating leptin concentrations drop 
significantly with changes in body fat  in response to decreasing energy stores [20].  Acutely, 
leptin concentrations have also been shown to significantly decrease during times of caloric 
restriction, as might occur during a period of fasting or dieting [56].  As discussed earlier, low 
leptin levels are interpreted by the hypothalamus as a state of energy deprivation, which triggers 
a cascade of hormonal responses that promotes a physiological state of energy conservation [18, 
44], such as a lower RMR.  While leptin is referenced as having an impact on RMR, there is little 
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support for this relationship.  Leptin has been shown to influence RMR in mice [57], while most 
human studies to date show no relationship between circulating leptin levels and metabolic rate 
[29].  Estrogen may also have effects on metabolic rate.  Resting metabolic rate has been shown 
to vary considerably with the menstrual cycle [58], an important factor to consider when 
characterizing metabolic health in premenopausal women.   
Fuel utilization, or the contribution of fat and/or carbohydrate being used as the primary 
fuel source at rest and during exercise may also be an important factor in weight regulation.  
Respiratory exchange ratio is the ratio of carbon dioxide production to oxygen consumption used 
to estimate substrate oxidation by way of indirect calorimetry [59].  An RER of 0.7 indicates 
primarily fat oxidation, while an RER of 1.0 indicates primarily carbohydrate oxidation, with a 
combination of the two falling within that range [59].  Diet seems to have the strongest impact on 
RER [60], with carbohydrate reliance increasing with chronic overfeeding, regardless of fat and 
carbohydrate content [61].  Larson et al. (1995) found that formerly obese individuals had 
significantly higher 24-hour and resting RER than normal weight subjects, indicating a chronic 
reliance on carbohydrate as a fuel source [62].  Kelley et al. (1999) also found obese individuals 
to have high glucose uptake and oxidation at rest, with little to no changes observed after 
feeding.  The lack of change in fuel utilization from rest may be an indication that obese 
individuals have impaired fat oxidation which may be associated with an increased risk of weight 
gain [31, 63].  Further, women tend to derive more of their energy from fat, while men derived 
more energy from carbohydrates [64, 65], but metabolic inflexibility may blunt these differences 
[66].  Despite potential relationships between obesity and sex on fuel utilization, RER in obese 
individuals is still highly variable, ranging anywhere from 0.799 a.u. to 0.903 a.u. [31, 67].  To 
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date, the relationship of total and regional body fat and RER in overweight and obese men and 
women has not been fully explored.  
Conclusion 
There is growing evidence that obesity is a multifaceted issue, with interconnected 
factors related to body composition, metabolic rate, fuel utilization, and hormonal balance.  The 
complications and potential factors that should be considered when evaluating the metabolic 
health of an obese individual extends far beyond what can be determined from a BMI category.  
In order to critically assess the impact excess body fat and altered body composition has on other 
aspects of metabolic health, the most sophisticated measurement techniques must be utilized.  
Using a 4C model to assess body composition provides a more accurate measure of FM, LM, and 
%fat over BMI, by accounting for additional compartments such as water and bone [68].  This 
level of precision provides a stronger basis from which to assess relationships of total body and 
regional fat distribution and LM with other aspects of metabolic health.  Further, US and DEXA 
are both validated techniques for evaluating VAT, which has important implications for clinical 
evaluation of metabolic health risk factors.  Specifically, US may be a feasible option for VAT 
quantification related to its portability and availability in many clinical settings, but the clinical 
utility requires further evaluation. 
Associations between hormones such as insulin, leptin, estrogen, and cortisol, have not 
been clearly established in their relationship to obesity.  Insulin resistance is associated with 
excessive total body fat, but not all obese individuals are insulin resistant.  Leptin has been 
shown to be positively associated with %fat, but with high between-subject variability.  There is 
also growing evidence for relationships between fat distribution and hormonal balance, but 
further evaluation of this relationship, especially in the context of sex differences, is needed.  
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Together, body composition and hormonal status may be associated with an altered state of 
energy balance and fuel utilization, promoting a state of weight gain and a resistance to weight 
loss.  Comprehensive evaluation of relationships between total body fat, fat distribution, LM, 
metabolic hormones, RMR, and RER, may prove valuable when characterizing overweight and 
obese populations, in hopes of gaining a better understanding of metabolic health.  
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CHAPTER III 
METHODOLOGY 
 
Subjects 
 Approximately 114 individuals provided initial interest in study participation.  After 
electronic correspondence, 64 individuals qualified to complete in-person inclusion/exclusion 
review.  After the in-person enrollment visits, eight individuals were excluded from participation 
based on violation of inclusion/exclusion criteria, resulting in a cohort of 56 individuals enrolled 
in the study.  An additional seven individuals withdrew from participation prior to testing for 
personal reasons.  Therefore, forty-nine overweight and obese men (n=23) and women (n=26) 
between the ages of 18 and 55 years participated in this study (Mean ± SD; Age=35.0 ± 8.9 yrs; 
BMI=33.6 ± 5.2 kg·m-2; %fat= 40.0 ± 7.3; Race: White=32; Black=13; Hispanic=2; Asian=2).  
Full subject characteristics stratified by sex can be found in Table 1.  Full recruitment and 
enrollment can be found in Figure 1.  All subjects were healthy, as reported on the health history 
questionnaire, having no history of medical or surgical events that may have significantly 
affected study outcome, including cardiovascular disease, diabetes, renal, hepatic, or 
musculoskeletal disorders.  Women were categorized as pre-menopausal, determined as 
reporting consistent menstruation for three months prior.  Subjects were considered overweight 
or obese, defined as having a BMI of >25kg·m-2 for women, >27 kg·m-2 for men, and/or having 
a %fat of >25%.  All subjects were considered weight stable, not having lost or gained greater 
than ten pounds within the three months prior to the enrollment date.  Subjects were not allowed 
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to participate in the study if they report using a meal replacement or dietary supplements 
including whey protein, beta-alanine, creatine, carnosine, or taurine within eight weeks prior to 
enrollment.  Subjects consuming a low-carbohydrate or ketogenic diet at the time of enrollment 
excluded from participation.  Subjects were not allowed to participate in the study if they have 
participated in another clinical trial within four weeks prior to enrollment.  Subjects agreed to 
maintain their usual activity lifestyle, abstain from smoking, caffeine, tobacco, and alcohol 
before testing days, provide written and dated informed consent, and were willing and able to 
comply with the testing protocol. 
Experimental Design 
 In a cross sectional design, subjects reported to the Applied Physiology Laboratory in 
Fetzer Hall to complete three different testing sessions (Figure 2).  Subjects were recruited from 
Chapel Hill, Raleigh, Durham, and the surrounding area by the use of flyers and word of mouth.  
Subjects who expressed interest in participating in the study were sent an electronic copy of the 
informed consent and a 4-day dietary intake log in which to record their dietary intake on two 
weekdays and two weekend days.  The dietary log, which is a standardized log used to obtain 
dietary information, was completed prior to visit one to allow time for dietary analysis.  During 
the first visit (enrollment), subjects provided written informed consent, completed a health 
history questionnaire, and completed anthropometric measures of height (cm; stadiometer: 
Perspective Enterprises, Portage, MI), weight (kg; digital scale: Health o meter: 2101KL, 
Bridgeview, IL), BMI, and age to ensure inclusion/exclusion criteria.  A baseline dietary analysis 
and interpretation was done for each participant based on the 4-day dietary food log to account 
for any baseline food influences and provided subjects with basic dietary recommendations.  
Dietary recommendations were standardized for all participants and based off of the Harvard 
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Healthy Eating Plate.  Following consent and enrollment, a two-week run in period, followed by 
a 24-hour dietary log, separated visit one and visit two in order to allow dietary intake to 
normalize.  To ensure normalization, the 24-hour dietary log recorded everything that was 
consumed during the 24 hours prior to visit two and was compared to intake reported from the 4-
day log.  Visit two consisted of measures of body composition, RMR, RERrest, and blood and 
salivary samples.  All tests were performed first thing in the morning.  Subjects arrived at least 
eight hours fasted (consuming no food or beverage except for water) wearing light-weight 
clothing; all metal and heavy plastic that could interfere with body composition measurements 
were removed.  Visit three consisted of a steady-state cardiorespiratory assessment.  Subjects 
arrived at least four hours fasted to visit three. Visits two and three were separated by 24 hours 
(±72 hours).  All devices were calibrated to manufacturer standards prior to testing to ensure 
valid results.    
Body composition 
Fat mass, LM, and %fat were calculated using a 4C model described by Wang et al. 
(2002) (Equation 1), where BV is total body volume, TBW is total body water, Mo is total body 
bone mineral density, and BM is body mass measured in kilograms [68]. 
Equation 1: FM (kg) = 2.748(BV) – 0.699(TBW) + 1.129(Mo) – 2.051(BM) 
  %fat = (FM/BM) × 100 
  LM (kg) = BM – FM  
Test-retest reliability for the 4C from our lab in a similar population are as follows:  fat mass 
intraclass correlation coefficient (ICC)=0.994, standard error of measure (SEM)=0.830 kg, and 
minimum difference (MD)=2.30 kg; %fat ICC=0.988, SEM=0.868%, MD=2.40%, and LM 
ICC=0.996, SEM=0.842 kg, MD=2.33 kg. 
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Air-displacement plethysmography (BodPod®, COSMED USA, Inc., Concord, CA, 
USA) was used to determine BV and BM.  In a private room, the subjects were asked to wear 
tight fitting clothing, such as a bathing suit or spandex, and given a swimming cap to wear on 
their head.  Identification code, age, sex, ethnicity, height (cm) and weight (kg), as measured 
using the scale connected to the device, were entered into the computer using the devices default 
software (Software Version 5.4.1, COSMED USA, Inc.).  Subjects were then asked to enter the 
BodPod®, breathe normally, and remain still for the duration of the test. 
Bioelectrical impedance spectroscopy (BIS; SFB7, ImpediMed, Queensland, Australia) 
uses a low voltage electrical current to estimate TBW.  Following manufacturer 
recommendations for preparation and placement, subject were asked to lie supine on a table with 
separation between the limbs.  Leads were connected to four electrodes placed on the right wrist 
(bisecting the ulnar head), five centimeters distally on the hand, the right ankle (bisecting the 
malleoli), and five centimeters distally on the foot.  The subject was instructed to lie still and 
breathe normally during the test.  This device scans 256 frequencies between the ranges of 4 and 
1000 kHz.  The average of two measurements was recorded for TBW.  
Dual-energy x-ray absorptiometry (DEXA; GE Lunar iDXA, GE Medical Systems 
Ultrasound & Primary Care Diagnostics, Madison, WI, USA) was used to estimate total body 
bone mineral content (BMC) and calculate Mo (Mo = BMC (kg) × 1.0436).  Total body scans 
were performed by trained DEXA technicians using default software (enCORE Software 
Version 16).  Prior to the scanning, identification code, age, sex, ethnicity, height (in) and weight 
(lbs) were entered into the computer.  The subject was asked to lie down on the DEXA table in 
the supine position and centered on the table within the scanning area.  The subject’s shoulders 
and hips were centered, with hands placed by the side of the legs in a prone position.  For those 
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wider than the scanning parameter (n= 6), the subject was shifted left-of-center to ensure a full 
scan of the right side of the body and left limbs were estimated from the right limbs, as suggested 
by the manufacturer.  Once positioned, a strap was secured around the ankles for comfort and 
subjects were instructed to lie still and breathe normally for the duration of the scan (7-13 min).    
Visceral Adipose Tissue 
Brightness-mode (B-mode) ultrasound (US) (GE LOGIQ-e, Software version R8.0.7, GE 
Healthcare, Wisconsin, USA) with standardized settings (Frequency: 4.0 MHz, Gain: 45) was 
used to quantify VAT.  While lying supine, a wide-band convex array ultrasound transducer 
(GE: C1-5 RS) with transducer gel was applied to the abdomen at the site of the linea alba, 5 cm 
proximal to the umbilicus.  The depth of the scan was adjusted as necessary to ensure full image 
capture of visceral adiposity.  Once positioned, the subject was asked to take a deep breath in, 
followed by a relaxed breath out; a still image of the abdomen was captured at the moment of 
complete exhale.  Visceral adipose tissue from the US (VATUS) was defined and quantified as 
the perpendicular distance between the interior border of the rectus abdominis and the posterior 
wall of the aorta [35].  The average of two measurements were recorded as VATUS.  Test-retest 
reliability for VATUS produced an ICC=0.99, SEM=0.35 cm, and minimum difference 
(MD)=0.69 cm. 
Dual-energy x-ray absorptiometry was also used to estimate VAT mass (VATDEXA).  
From the previously described total body scan, VATDEXA was defined as the automatically 
selected android region-of-interest set by DEXA software.  This region was pre-programmed to 
quantify abdominal fat spanning between the top of the iliac crest to 20% of the distance from 
the top of the iliac crest to the base of the skull (Figure 3B) [69]. 
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Resting metabolic rate 
Resting metabolic rate and RERrest were evaluated using a ventilated canopy with indirect 
calorimetry.  Prior to measurements, the hood was calibrated to manufacture’s standards with a 
gas mixture of known concentrations of oxygen and carbon dioxide.  While lying in a supine 
position, subjects were fitted with the ventilated canopy.  The canopy was placed over the 
subjects head and secured comfortably around the neck and arms, ensuring that no air could 
penetrate the sealed canopy.  Subjects were asked to relax and breathe normally for 30 minutes.  
Respiratory gases, oxygen uptake, and carbon dioxide production, were analyzed breath-by-
breath with a metabolic cart (TrueOne 2400, ParvoMedics, Inc., Sandy, UT).  During the first 
five minutes of the test, the dilution rate was adjusted until the fraction of expired carbon dioxide 
was between 1.0-1.2%.  This portion of the test was excluded to account for normalization and 
the mean RMR and RERrest were recorded from the remaining 25 minutes of the test.  Test-retest 
reliability for RMR from our lab produced an ICC=0.94, SEM=125.6 kcal·day-2 and MD=244.3 
kcal·day-2, and RERrest was ICC=0.83, SEM=0.03 and MD=0.05. 
Blood Lipid and Hormone Analysis 
All blood draws were done in the Applied Physiology Lab by an individual trained in 
phlebotomy in accordance with bloodborne pathogen precautions established by UNC’s 
Occupational Health Services.  A 4 ml sample from the region of the antecubital vein was 
collected and analyzed using established enzymatic assays for fasting blood glucose (GLUC), 
total cholesterol (TC), triglycerides (TRG), high-density lipoproteins (HDL), low-density 
lipoproteins (LDL), insulin, and leptin.  Samples were analyzed by the Biobehavioral Lab 
(Chapel Hill, NC).  Lipid profiles were analyzed within 15 minutes of the draw. 
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Salivary Hormone Analysis 
 A 1.0-2.0 ml saliva sample was obtained and analyzed for estradiol and cortisol 
concentrations.  To avoid blood contamination, subjects avoided brushing their teeth for 45 
minutes prior and undergoing dental work for 48 hours prior to sample collection.  Immediately 
upon arrival and prior to sample collection, subjects rinsed their mouth with water to remove any 
residues.  All samples were kept frozen at -20°C until analysis.  Samples were analyzed by the 
Biobehavioral Lab (Chapel Hill, NC) using established enzymatic assays. 
Steady-state cardiorespiratory assessment 
A steady-state cardiorespiratory assessment was used to evaluate RER during exercise 
(RERbike).  Once fitted with HR monitor and connected via breathing tube to an indirect 
calorimetry system (TrueMax 2400, Parvo Medics, Salt Lake City, UT), individuals were 
allowed a three minute warm-up on a cycle ergometer (Lode, Gronigen, The Netherlands) at a 
self-selected speed and workload of 20W.  After three minutes, the workload was manually 
increased until heart rate (HR) correlated to 50-60% heart rate reserve (HRR).  Once HR was 
within five beats per minute of the target HRR, respiratory gases were analyzed breath-by-breath 
via open-circuit spirometry for 20 minutes to measure RERbike.  Heart rate was monitored 
throughout the test using a Polar heart rate monitor (Polar FT1, Polar USA, Port Washington, 
NT, USA) and workload was adjusted throughout the test as necessary to maintain 50-60% HRR.  
Heart rate reserve was calculated using the Karvonen formula (HRR = [HRmax – HRrest] x 
%intensity + HRrest) where HRmax is age predicted maximal HR (HRmax = 220 – age) and HRrest is 
resting HR, the average HR achieved during the resting metabolic rate test.  To assess potential 
metabolic inflexibility, change in respiratory exchange ratio (ΔRER) was calculated as the 
difference between RERbike and RERrest. 
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Statistical Analysis 
This study was a portion of a larger study assessing the effects of a breakfast meal 
replacement on body composition and metabolic characteristics of overweight and obese adults.  
Power calculations for this study were conducted using nQuery version 7.0.  Using mean and 
standard deviation values from a similar population [70], a sample of 50 subjects was 
determined, providing a power of at least 80% for a repeated measures ANOVA with 
significance of α = 0.05.  This sample size also accounted for a loss of a predicted five subjects 
(10%).  Power calculations for the larger study were calculated for a higher order statistical 
calculation and provide sufficient power (>80%) for the current study.  
To characterize metabolic health, each metabolic variable was stratified into categories 
associated with accepted reference ranges.  Frequency rates for each category were calculated 
within each variable.  Individuals were categorized as overweight (25-29.9 kg·m-2), obese (30-
34.9 kg·m-2), obese II (35-39.9 kg·m-2), or obese III (≥ 40.0 kg·m-2) to assess metabolic disease 
risk based on BMI [71].  Based on %fat, individuals were categorized as moderate (M<25%; 
F<38%) or high risk (M≥25%; F≥38%) [72].  High TRG, low HDL, high GLUC, and VATUS 
were used characterize individuals based on metabolic syndrome risk factors [73]; VATUS was 
substituted for the traditional waist circumference risk factor.  Individuals were further 
characterized based on other markers of metabolic health.  Lean mass index (LMI; LM(kg)·m-2) 
was used to stratify LM measured by DEXA based on normative values for sex, race, and age 
[74].  Visceral adipose tissue thickness was stratified as low (<7cm), moderate (M=7-9cm; W=7-
8 cm), or high (M>9cm; W>8cm) [35].  Resting metabolic rate was stratified as low (<125.6 
kcal/d below predicted), normal (±125.6 kcal/d of predicted), or high (>125.6 kcal/d above 
predicted).  Resting metabolic rate stratification was based on the difference between predicted 
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and measured metabolic rate (predicted – measured) using the Harris-Benedict prediction 
equation [75].  Resting RER was stratified as low (<0.82), normal (0.85±0.03) or high (>0.88).  
High and low cutoff values were set at the SEM for RMR and RERrest.  Glucose, lipids and 
hormones were stratified according to standard clinical metabolic diagnoses (Table 3) [1, 76-80].  
Estradiol and cortisol stratification was based off of Salimetrics reference data.  Insulin 
resistance was assessed by calculating HOMA-IR as described by Levy et al. (1998) [79, 80].  
Individuals were categorized as normal (≤2.5) or high (>2.5) according to their calculated 
HOMA-IR [81, 82].  
A Pearson product-moment correlation was used to identify significant relationships 
between body composition (FM, LM, %fat, VAT), RMR, RERrest, RERbike, GLUC, lipids, and 
hormones (insulin, leptin, estrogen, cortisol), and in addition to relationships between leptin, 
RMR, RERrest, and RERbike.  Separate Pearson product-moment correlations were used to 
identify significant relationships by sex between these same variables.  
A one-way analysis of variance (ANOVA) was used to evaluate significant differences in 
RMR, RERrest, RERbike, GLUC, lipids, and hormones (insulin, leptin, estrogen, cortisol), and 
between males and females.  A separate one-way ANOVA was used to evaluate differences in 
these same variables between overweight and obese individuals (overweight = BMI < 30.0, 
Obese = BMI ≥ 30.0).  Separate analysis of co-variances (ANCOVA) were used to evaluate 
significant differences in RMR, RERrest, RERbike, GLUC, lipids, and hormones (insulin, leptin, 
estrogen, cortisol) between males and females and overweight and obese individuals when co-
varying for differences in LM.  
A multiple regression analysis was used to assess the variances in body composition (FM, 
LM, %fat, VAT) and RMR, RERrest, and RERbike using standard clinical measures (GLUC, 
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lipids, insulin, leptin, estrogen, cortisol).  Visceral adipose tissue (VATUS) was included as a 
potentially feasible clinical factor when evaluating variance in FM, LM, and %fat.  All statistical 
analyses were completed using SPSS (Version 21, IBM, Armonk, NY, USA), using a 
significance of α = 0.05 to determine statistical significance. 
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CHAPTER IV 
RESULTS 
 
Based on BMI and %fat categorization, all individuals were considered to be at an 
increased metabolic disease risk (Table 2).  Twenty-two (45.3%) individuals were considered to 
be at a very high risk, with a BMI ≥ 35 kg·m-2.  All individuals were considered to be at a high 
risk based on %fat, except for one who was considered to be at a moderate risk, but was 
borderline high risk (F; 37.6%fat).  When evaluating the combined risk factors for metabolic 
syndrome (abdominal obesity, elevated TRG, low HDL, and elevated fasting glucose), 32 
individuals (71.1%) had no more than one risk factor (Table 2).  Only one individual had three 
risk factors (2.2%), meeting the criteria for metabolic syndrome.  When additional novel factors 
were used to evaluate metabolic risk (LMI, RMR, RERrest, TC, LDL, HOMA-IR) the frequency 
of individuals with three or more risk factors increased to 48.8% (n=22). Frequencies of 
individual metabolic risk factors are presented in Table 3. 
Body Composition   
Research Question: Is there a relationship between total and regional body composition, RMR, 
RERrest, RERbike, glucose, lipids, and hormones in overweight and obese adults?  
Research Question: Are there differences in total and regional body composition, RMR, 
RERrest, RERbike, glucose, lipids, and hormones between overweight and obese adults? 
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Fat Mass 
For the entire group FM ranged from 24.54 - 75.05 kg.  For the entire group, FM was not 
significantly correlated with RMR (p=0.163), RERrest (p=0.711), RERbike (p=0.691), or ΔRER 
(p=0.918).  Fat mass was significantly positively correlated with insulin (p=0.000, r=0.665), 
estradiol (p=0.003, r=0.417), and leptin (p=0.000, r=0.654), but not cortisol (p=0.812).  There 
were no significant correlations between FM, TC (p=0.742), TRG (p=0.168), HDL (p=0.534), 
LDL (p=0.458), or GLUC (p=0.734).  There was also no correlation between FM and VATUS 
(p=0.264, r=0.163).  
When comparing differences between overweight and obese individuals, obese 
individuals had greater FM, than overweight individuals (p<0.001; OB=42.50 ± 10.63 kg; OW= 
30.15 ± 4.00 kg).  When comparing differences between males and females, females had 
significantly greater FM than males (p=0.006; F=43.14 ± 11.03 kg; M=34.80 ± 8.83 kg).  In 
males, greater FM was positively associated with RERrest (p=0.028, r=0.459), insulin (p=0.004, 
r=0.580), estradiol (p=0.003, r=0.417), and leptin (p=0.000, r=0.765); associations with RMR 
approached significance (p=0.061, r=0.396).  In females, greater FM was associated with greater 
VATUS (p=0.077, r=0.353), higher RMR (p=0.028, r=0.459), insulin (p<0.001, r=0.704), and 
leptin (p=0.004, r=0.587). 
 
Lean Mass 
For the entire group LM ranged from 39.10 - 85.48 kg.  When evaluating LM based on 
LMI, 33 individuals had “normal” LM (LM: 39.10 - 74.50 kg), while 16 individuals had “high” 
LM (LM: 46.45 – 85.48 kg).  Five individuals, all of whom were females, had a LMI greater 
than two standard deviations (>97th percentile; LM: 56.05 – 75.15 kg), suggesting higher than 
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average LM for sex, age, and race (Figure 5).  These five females all demonstrated a %fat of 
>40% and had normal metabolic rates, TC, TRG, and GLUC.  Four of the five also had normal 
LDL and low cortisol levels. No individuals were categorized with ‘low’ LM.  Lean mass was 
significantly positively correlated with VATUS (p=0.024, r=0.323) and RMR (p<0.001, r=0.900), 
but not RERrest (p=0.080), RERbike (p=0.337), or ΔRER (p=0.918, p=0.015).  There was a 
significant positive correlation between LM and insulin (p=0.075, r=0.268), a negative 
correlation with leptin (p=0.026, r= -0.332), and no relationship with cortisol (p=0.854, r= -
0.027) or estradiol (p=0.407, r=0.121).  Lean mass was positively correlated with TRG (p=0.009, 
r=0.384) and negatively correlated with HDL (p=0.003, r= -0.438).  There was no correlation 
with TC (p=0.502, r=0.103), LDL (p=0.440, r= 0.118) or GLUC (p=0.121, r=0.235).   
 When comparing differences between overweight and obese, obese individuals had 
greater LM than overweight individuals (p=0.010; OB=61.31 ± 11.64 kg; OW=51.42 ± 10.70 
kg).  When comparing differences between males and females, males had significantly greater 
LM than females (p<0.0001; M=67.35 ± 8.54 kg; F=51.02 ± 9.35 kg).  In males, greater LM was 
positively associated with RMR (p<0.001, r=0.871), RERrest (p=0.039, r=0.433), insulin 
(p=0.005, r=0.562), estradiol (p=0.002 r=0.605), and TRG (p=0.057, r=0.402); associations with 
HDL approached significance (p=0.055, r= -0.406).  In females, greater LM was positively 
associated with RMR (p<0.001, r=0.871) and insulin (p=0.017, r=0.503). 
 
Percent Body Fat 
For the entire group, %fat ranged from 25.42 - 52.78%.  For the entire group, %fat was 
not correlated with VATUS (p=0.531).  Percent body fat was negatively correlated with RMR 
(p=0.001, r= -0.467), but not RERrest (p=0.377), RERbike (p=0.826), or ΔRER (p=0.652).  Percent 
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body fat was positively correlated with insulin (p=0.013, r=0.369), estradiol (p=0.048, r=0.284), 
and leptin (p=0.000, r=0.829), but not with cortisol (p=0.923).  Percent body fat was positively 
correlated with HDL (p=0.006, r=0.404) and negatively correlated with TRG (p=0.003, r= -
0.426); there was no correlation with TC (p=0.897) LDL (p=0.716), or GLUC (p=0.486).   
There was no difference in %fat between overweight and obese individuals (p=0.146).  
When comparing differences between males and females, females had significantly higher %fat 
than males (p<0.001; F=45.48 ± 4.12%; M=33.78 ± 4.76%).  In males, a greater %fat was 
positively associated with leptin (p<0.001, r=0.700).  In females, a greater %fat was positively 
associated with insulin (p=0.011, r=0.531), leptin (p=0.001, r=0.635), and LDL (p=0.031, 
r=0.460); associations with RERrest (p=0.051, r= -0.387) and TC (p=0.077, r=0.385) approached 
significance.  
 
Visceral Adipose Tissue 
Research Question:  Are there differences in relationships between VAT and markers of 
metabolic health when measured via B-mode US or dual-energy x-ray absorptiometry (DEXA)? 
For the entire group, VATUS ranged from 2.21 - 10.55 cm.  Thirty-six individuals 
(73.5%) were considered at low CVD risk (2.21 – 6.77 cm), 10 were at a moderate risk (7.32 – 
8.58 cm), and three were at a high risk (8.83 – 10.55 cm).  For the entire group, there was no 
significant correlation between VATUS, RMR (p=0.078), RERrest (p=0.783), RERbike (p=0.797), 
or ΔRER (p=0.967).  There was no significant correlation between VATUS, insulin (p=0.143), 
cortisol (p=0.078), estradiol (p=0.516), or leptin (p=0.919).  There was no significant correlation 
between VATUS, GLUC (p=0.297), TC (p=0.411), TRG (p=0.975), HDL (p=0.136), and LDL 
(p=0.130). 
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There were no significant difference in VATUS between overweight and obese individuals 
(p=0.959).  Differences between males and females approached significance (p=0.053), with 
males having more VATUS than females (M=6.53 ± 1.93 cm; F=5.53 ± 1.62 cm).  In males, there 
was no association between VATUS and metabolic factors.  In females, VATUS was positively 
associated with insulin (p=0.009, r=0.545) and leptin (p=0.012, r=0.523).  When accounting for 
differences in LM between males and females, there was no significant difference in VATUS 
(p=0.570). 
When measured by DEXA, VATDEXA was positively associated with RMR (p<0.001, 
r=0.577), insulin (p=0.002, r=0.455), and estradiol (p=0.075, r=0.256) and negatively associated 
with HDL (p=0.024, r= -0.336); associations with RERrest (p=0.062, r=0.269), TC (p=0.088, 
r=0.257), and LDL (p=0.062, r=0.280) approached significance.  There was not a significant 
difference in VATDEXA between overweight and obese individuals (p=0.142).  When comparing 
differences between males and females, males had greater VATDEXA than females (p=0.011; 
M=3.4 ± 1.7 lbs; F=2.3 ± 1.1 lbs).  In males, VATDEXA was positively associated with RERrest 
(p=0.029, r=0.456), insulin (p<0.001, r=0.674), TC (p=0.010, r= 0.525), and LDL (p=0.037, r= 
0.437); associations with RMR (p=0.076, r=0.377) and estradiol (p=0.061, r=0.397) approached 
significance.  In females, VATDEXA was positively associated with RMR (p<0.001, r=0.654), 
insulin (p=0.004, r=0.588), and estradiol (p=0.030, r=0.425) and negatively associated with HDL 
(p=0.018, r= -0.499). 
 
Metabolic Rate 
Research Question:  Are there differences in RMR, RERrest, RERbike, glucose, lipids, and 
hormones between men and women, when accounting for dietary intake and body composition? 
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For the entire group, RMR ranged from 1292 - 2466 kcal/d.  Twenty-two individuals 
(44.9%) had lower than predicted RMR, while three individuals had higher than predicted RMR 
(Figure 6).  When comparing differences between overweight and obese, obese individuals had a 
higher RMR than overweight individuals (p=0.002; OB = 1894.75 ± 301.60 kcal/d; OW = 
1587.46 ± 216.45 kcal/d); when controlling for differences in LM, there was no significant 
difference between overweight and obese individuals (p=0.096).  When controlling for body 
mass, RMR was positively correlated with LM (p<0.001, r=0.764) and negatively correlated 
with FM (p<0.001, r=-0.764) and %fat (p<0.001, r=-0.758); there was no significant correlation 
with VATUS or VATDEXA (p>0.05).  When comparing differences between males and females, 
males had significantly higher RMR than females (p<0.001; M=2011.13 ± 259.01 kcal/d; 
F=1638.15 ± 242.76 kcal/d).  When accounting for differences in LM, there was no significant 
difference in RMR between males and females (p=0.873).  When accounting separately for 
differences in CHO, FAT, PRO, and CAL, males had a higher RMR than females (p<0.001).  
When controlling for body mass in males, RMR was positively correlated with LM (p=0.005, 
r=0.572) and negatively correlated with FM (p=0.005, r=-0.572) and %fat (p=0.006, r=-0.562).  
When controlling for body mass in females, RMR was negatively correlated with %fat (p=0.038, 
r=-0.417); relationships with LM and FM approached significance (p=0.057, r=0.386 and 
p=0.057, r=-0.386).  There was no significant correlation between VATUS or VATDEXA in males 
or females (p>0.05). 
For the entire group, RERrest ranged from (0.77 - 0.98 a.u.).  Eight individuals had a 
RERrest greater than 0.88 a.u., indicating a higher reliance on carbohydrate metabolism at rest 
compared to 13 individuals who had a RERrest less than 0.82 indicating greater reliance on fat 
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metabolism at rest.  There was no significant difference in RERrest between overweight and obese 
individuals (p=0.493) or between males and females (p=0.638).  When accounting separately for 
differences in LM, CHO, FAT, PRO, and CAL intake between males and females, there was no 
significant difference in RERrest (p>0.05). 
For the entire group, RERbike ranged from 0.85 to 1.19 a.u.  Forty-five individuals 
(91.8%) individuals had a RERbike greater than 0.88, indicating greater reliance on CHO during 
steady-state exercise.  There was no significant difference in RERbike between overweight and 
obese individuals (p=0.344) between males and females (p=0.678).  When accounting separately 
for differences in LM, CHO, FAT, PRO, and CAL intake, there was no significant difference in 
RERbike between males and females (p>0.05). 
 For the entire group, ΔRER ranged from -0.01 to 0.31 a.u.  There was no significant 
difference in ΔRER between overweight and obese individuals (p=0.695) or between males and 
females (p=0.964).  When accounting separately for differences in LM, CHO, FAT, PRO, and 
CAL intake, there was no significant difference in ΔRER between males and females (p>0.05). 
 
Lipids and glucose 
Average lipid and GLUC values for the entire group and between males and females are 
presented in Table 1.  Males had significantly higher TRG (p=0.004), while females had 
significantly higher HDL (p=0.002).  There were no significant difference between males and 
females for TC (p=0.320), LDL (p=0.274) or GLUC (p=0.086).  There was no significant 
difference in blood lipids or GLUC between overweight and obese individuals (p>0.05).  When 
accounting for differences in LM, there was no significant difference in blood lipids or GLUC 
between males and females (p>0.05).  
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Hormones 
Research Question: Is there a relationship between leptin, RMR and RERrest, RERbike? 
Average hormonal values for the entire group and between males and females are 
presented in Table 1.  All individuals had normal or high leptin levels (Mean: 36.09 ± 28.95 
ng/mL; Range: 3.90 – 103.17 ng/mL).  There was a non-significant negative correlation between 
leptin and RMR, (p=0.084, r= -0.261); there was no correlation between leptin, RERrest 
(p=0.700), RERbike (p=0.941), or ΔRER (p=0.837).  Differences in leptin between overweight 
and obese individuals approached significance with obese individuals having higher leptin levels 
(p=0.053; OB=41.09 ± 31.03 ng/mL; OW=22.33 ± 16.41 ng/mL).  Females had significantly 
higher leptin than males (p<0.0001; F=58.11 ± 25.23 ng/mL; M=15.02 ± 10.93 ng/mL).  When 
accounting for differences in LM, females had greater leptin than males (Mean difference ± 
SEM; 1.09 ± 0.28 ng/mL). 
Average cortisol levels were 0.28 ± 0.15 µg/dL (0.08 – 0.71 µg/dL).  No individuals had 
high cortisol levels, but seven individuals were considered to have low cortisol levels based on 
sex and age (0.08 – 0.25 µg/dL).  Difference in cortisol between overweight and obese 
individuals approached significance (p=0.063) with obese individuals having higher cortisol 
(0.31 ± 0.16 µg/dL) than overweight individuals (0.23 ± 0.10 µg/dL).  There was no significant 
difference in cortisol levels between males and females (p=0.784).  When accounting for 
differences in LM, there was no significant difference in cortisol levels between males and 
females (p=0.589). 
Average estradiol was 1.99 ± 0.82 pg/mL; eleven individuals had low estradiol levels 
(0.63 – 1.33 pg/mL), eight of whom were males.  Three individuals had high estradiol levels 
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(3.13 – 5.46 pg/mL), two of whom were also males.  Obese individuals had higher estradiol 
levels than overweight individuals (p=0.035; OB=2.14 ± 0.85 pg/mL; OW=1.58 ± 0.57 pg/mL).  
Differences in estradiol between males and females approached significance (p=0.052), with 
females having higher estradiol levels than males (F=2.20 ± 0.81 pg/mL; M=1.75 ± 0.76 pg/mL).   
Average insulin was 9.68 ± 7.36 uIU/mL.  There was no significant difference in insulin 
between overweight and obese adults (p=0.143). There was no significant difference in insulin 
between males and females (p=0.263), but when accounting for differences in LM, males had 
significantly higher insulin levels than females (p=0.001) (Mean difference ± SEM: 8.74 ± 2.52 
uIU/mL). 
 
Regression Analysis 
Research Question:  Will variances in total and regional body composition, RMR, RERrest, 
RERbike, and ΔRER be explained by blood and hormonal markers of metabolic health? 
Standard clinical measures (GLUC, lipids, insulin, leptin, estrogen, cortisol) were used as 
predictors for non-standard clinical measures (FM, LM, %fat, VAT, RMR, RERrest, RERbike, 
ΔRER).  For body composition: 59.8% of the variance in FM was explained by insulin (p<0.001, 
β=0.681) and leptin (p<0.001, β=0.166) (p=0.000, r=0.773, r2=0.598); 72.4% of the variance in 
LM was explained by HDL (p=0.009, β= -0.348) and VATUS (p=0.050, β=1.813) (p=0.002, 
r=0.851, r2=0.724); 72.4% of the variance in %fat was explained by leptin (p<0.001, β=0.187) 
and HDL (p=0.022, β=0.108) (p=0.000, r=0.851, r2=0.724); no standard clinical measures 
significantly explained the variances in VATUS, compared to 28.9% of the variance in VATDEXA 
explained by insulin (p=0.003, β=0.089) and TRG (p=0.033, β=0.006).    
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 In males, 60.2% of the variance in FM was explained by leptin (β=0.627) (p=0.000, 
r=0.766, r2=0.602); 36.6% of the variance in LM was explained by estradiol (β=6.658) (p=0.002, 
r=0.605, r2=0.366); 64.3% of the variance in %fat was explained by leptin (p<0.001, β=0.320) 
and HDL (p=0.008, β=0.237) (p=0.000, r=0.802, r2=0.643); no standard clinical measures 
significantly explained the variances in VATUS.  In females, 49.6% of variances in FM were 
explained by insulin (β=0.870) (p=0.000, r=0.704, r2=0.496); 25.3% of the variance in LM was 
explained by insulin (β=0.532) (p=0.000, r=0.704, r2=0.496); 55.0% of the variance in %fat was 
explained by leptin (p=0.001, β=0.085) and LDL (p=0.022, β=0.037) (p=0.001, r=0.742, 
r2=0.550); 29.7% of the variance in VATUS was explained by insulin (β=0.090) (p=0.009, 
r=0.545, r2=0.297).  
 For metabolic rate: 18.4% of the variances in RMR were explained by HDL (β= -10.255) 
(p=0.003, r=0.429, r2=0.184); 11.4% of the variance in RERrest was explained by HDL (β= -
0.001) (p=0.024; r=0.337; r2=0.114); 14.7% of the variance in RERbike was explained by 
estradiol (β=0.028) (p=0.005, r=0.166, r2=0.147); 12.0% of the variance in ΔRER was explained 
by estradiol (β=0.026) (p=0.020, r=347, r2 = 0.120). 
In males, 42.5% of the variance in RMR was explained by estradiol (β=216.977) 
(p=0.001, r=0.649, r2=422); 27.5% of the variances in RERrest was explained by insulin 
(β=0.004) (p=0.010, r=525, r2=0.275); 24.0% of the variance in RERbike was explained by 
estradiol (β=0.041) (p=0.018, r=0.490, r2=240); no standard clinical measures significantly 
explained the variances in ΔRER.  In females, 32.5% of the variance in RMR was explained by 
insulin (β=15.353) (p=0.006, r=0.570, r2=0.325); 19.8% of the variance in RERrest was explained 
by TC (β= -0.001) (p=0.038, r=0.445, r2=0.198); 18.8% of the variance in RERbike was explained 
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by estradiol (β=0.027) (p=0.044, r=0.434, r2=0.188); no standard clinical measures significantly 
explained the variances in ΔRER. 
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CHAPTER V 
DISCUSSION 
 
Metabolic dysfunction is commonly associated with obesity, excess VAT, dyslipidemia, 
insulin resistance, and hormonal imbalances [8, 73, 83].  While blood lipids, GLUC, and insulin 
levels are common indicators of metabolic dysfunction, not all obese individuals have 
dyslipidemia or insulin resistance, despite excess adiposity [9, 10, 84].  Other components of 
body composition, such as LM and VAT, have been shown to have strong influences on 
metabolic factors [12, 13, 30, 83, 85], yet are not assessed using common clinical measures such 
as BMI and waist circumference.  Further, in the absence of dyslipidemia or insulin resistance, 
other measures such as RMR and RER, may provide early indication of metabolic dysfunction. 
Results of the current study indicate that FM alone was not significantly correlated with 
traditional markers of metabolic health (blood lipids and GLUC) in otherwise healthy overweight 
and obese adults, but may be linked with hormonal profiles, showing positive correlations with 
insulin, leptin, and estradiol.  Fat distribution however, may have stronger associations with 
metabolic dysfunction.  Women with greater FM tended to have more VATUS which was 
significantly correlated with higher insulin and leptin levels.  In males, VATUS was not 
associated with FM, but VATDEXA significantly correlated with TC, LDL, and insulin, potentially 
placing men at a greater risk for metabolic dysfunction, even in the absence of excess total body 
fat.  While fat distribution has negative associations with metabolic health, LM in the presence of 
excess FM may have positive benefits [30].  In the present study, a greater %fat was associated 
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with a lower RMR, while greater LM was associated with a higher RMR.  Lean mass may be 
especially important in women with very high %fat, as those with above average LM in the 
present study tended to have normal metabolic rates, TC, LDL, TRG, GLUC, and low cortisol 
levels, though further investigation into these relationships is necessary.  Despite 16.3% of the 
group exhibiting increased carbohydrate reliance at rest (RERrest >0.88), body composition did 
not seem to have strong associations with fuel utilization during rest or steady-state, which may 
implicate the role of diet and exercise in metabolic health. 
 Obesity based disease risk is often clinically evaluated using BMI.  Based on BMI, all 
individuals in the group were considered at an elevated disease risk.  However, when evaluating 
common risk factors of metabolic syndrome, almost 1/3 of the group displayed no metabolic risk 
factors indicating that outside of excess body fat, these individuals could be considered to be 
relatively metabolically healthy at the time of testing.  These findings may also indicate that this 
form of diagnosis may only be identifying individuals who have reached a certain level of 
metabolic dysfunction.  Health based evaluations from BMI do not properly take into account fat 
distribution or the presence of LM, both of which have significant roles in metabolic health [9, 
30].  Traditional metabolic syndrome criteria accounts for the influence of fat distribution on 
metabolic health, but uses waist circumference as its standard measure which does not 
differentiate between abdominal subcutaneous and VAT [73, 86].  Similarly, BMI does not 
quantify LM which may have important implications for insulin sensitivity and glucose uptake 
[30, 50].  Metabolic rate and RER may also be early signs of metabolic dysfunction.  Low 
relative metabolic rate and high carbohydrate reliance at rest have been shown to be associated 
with weight gain [67, 87], potentially contributing to the development of metabolic dysfunction.  
When accounting for other risk factors not evaluated in traditional metabolic syndrome criteria, 
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in addition to the traditional criteria, individuals with two or more metabolic risk factors 
increased from about 29% to 80%, indicating that consideration of these factors when evaluating 
metabolic health may be warranted. 
Excess adiposity is known to be associated with insulin resistance and dyslipidemia [88], 
but more recent studies have identified individuals with up to 50% body fat who have normal 
insulin sensitivity and blood lipids [11, 84].  Fat mass has been shown to be positively correlated 
with insulin resistance, even in normal weight individuals [38].  Further, insulin resistance has 
been shown to be significantly related to elevated TRG, LDL, and VAT [11]. While results of 
the current study support clear associations between all indices of excess fat accumulation (FM, 
%fat, and VAT) and insulin, FM was not associated with blood lipids or GLUC in males or 
females.  Interestingly, FM was positively associated with VATUS in women, but not in men, 
likely related to differences in hormonal distribution of fat.  Hormones such as leptin, estrogen, 
and cortisol are commonly associated with FM and fat distribution [15].  In the current study, 
greater FM and %fat were associated with higher estradiol and leptin, but not cortisol.  When 
separated by sex, FM was associated with greater estradiol in men, but not in women, supporting 
previous findings of elevated estradiol levels in obese men [23, 24]. 
Visceral adipose tissue has been repeatedly shown to be associated with increased risk of 
metabolic syndrome [89-91], having strong associations with insulin resistance, dyslipidemia, 
and hormonal imbalances in obese and normal weight individuals [35, 90, 92].  One outcome of 
the current study was to assess relationships between VAT and markers of metabolic health 
using B-mode US.  B-mode US may be a more accurate and affordable method of quantifying 
VAT especially in clinical settings where the gold standard CT-scan is costly and potentially 
impractical [42, 43].  In the current study, VATUS ranged from 2.21 – 10.55 cm and was 
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significantly correlated with insulin and leptin in women.  While greater VAT is typically 
associated with greater metabolic risk in both men and women, Leite et al. (2002) found that a 
VAT thickness greater than 8 cm was associated with high risk in women compared to 9 cm in 
men.  These results, in combination with those of the current study, may indicate that VAT 
accumulation in women may be a more serious metabolic risk factor.   
Quantification of VAT from a total body DEXA scan is another valid alternative to CT 
[69].  Ultrasound is commonly criticized for having poor reliability, related to differences in 
measurement technique [36, 93], which is eliminated by the DEXA quantification.  Test-retest 
reliability calculations for VATUS in the current study showed good reliability, but when 
comparing the two methods, VATDEXA was significantly correlated with more markers of 
metabolic health, including insulin and blood lipids, especially in men.  Differences in the degree 
of the association between the two measures may be related to how VAT is quantified by each 
device.  Ultrasound quantifies thickness of VAT within the abdomen and may include organ 
tissue, while VATDEXA is quantified by mass and volume.  Both measurements have been shown 
to be significantly correlated with CT measurements of VAT [42, 69], but differences in VAT 
quantification should be considered in future research.  Nevertheless, both methods still have 
significant benefits over waist circumference in determining potential cardiometabolic risk [35, 
91]. 
Lean mass is a major site for glucose uptake and substrate oxidation within the body, 
potentially having a beneficial impact on improving insulin sensitivity, lowering blood lipids, 
and increasing metabolic rate [29, 30].  Contrary to what might be expected, current results 
showed that greater LM was associated with VATUS, insulin, TRG, and low HDL.  Other studies 
have noted a similar relationship between greater LM and poor markers of metabolic health [84, 
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94-96].  One study demonstrated that obese women with less LM had favorable metabolic 
profiles compared to obese women with unfavorable metabolic profiles [84].  When comparing 
differences between women with high and low LM, Brochu et al. (2008) found that higher LM 
was positively associated with insulin and GLUC.  As was supported in the current study, obese 
individuals often have a greater quantity of LM, likely as a result of supporting greater body 
weight, but may not always have a higher quality of LM [97, 98].  Greater total body fat has been 
correlated to greater intramuscular fat and may support the indirect relationship between LM, 
VAT, and insulin in the present study [50, 97, 99].  It should be noted that five individuals in the 
current study were identified as having above average LM.  All were females, and all tended to 
have normal TC, LDL, TRG, GLUC, and insulin resistance based on HOMA-IR.  While this 
observation cannot be extrapolated to the larger population and muscle quality was not 
measured, it may support previous findings demonstrating a benefit of LM in an obese 
population [30].  Due to the concomitant increase in LM with FM, future considerations for 
muscle quality in this population should be explored. 
Lean mass also has an important contribution to metabolic rate and fuel utilization.  Lean 
mass is more metabolically active than FM, with one study showing that LM accounted for up to 
63% of the inter-individual variability in RMR, compared to less than 9% from FM [100].  In the 
current study, a higher metabolic rate was associated with greater LM and lower %fat.  Across 
the entire group, FM was not associated with RMR or RER, however, obese individuals had a 
higher RMR than overweight individuals.  Further FM and VATDEXA were associated with a 
higher RMR in women, suggesting a potential influence of overall greater body size on RMR.  
Obese individuals often have a higher metabolic rate compared to normal weight individuals by 
association of having a greater body mass [101].  Conversely, when metabolic rate is evaluated 
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relative to LM and FM, some studies suggest obese individuals may actually have a lower RMR 
[102, 103].  About 45% of individuals in the current study had a lower than predicted metabolic 
rate, compared to only 6% who had greater than predicted.  Similarly, when controlling for body 
mass, a lower metabolic rate was associated with FM and %fat suggesting a potential negative 
association between excess fat and RMR.  
Based on the results of the current study, a higher RERrest was associated with greater 
LM, FM, and VATDEXA and may represent a greater reliance on carbohydrates.  Despite 
influences of body composition on metabolic rate and fuel utilization, RMR and RER are still 
highly variable between individuals [104].  In the present study, RER values at rest ranged from 
0.77 – 0.98 a.u., with similar ranges reported from other studies [31, 67].  Some variances in 
RER have previously been shown to be hormonally influenced [105].  Specifically, leptin, a 
signal of chronic energy storage, may indirectly alter RMR and fuel utilization [44, 106].  
However, no significant relationships between leptin, RMR or RER were found in the current 
study. 
Blood lipid profiles are a common marker of metabolic health and are part of routine 
assessments in clinical settings.  On the other hand, hormonal imbalances can have profound 
effects on fat distribution, metabolic regulation, hunger, and satiety [15, 19, 44, 107], but are less 
often evaluated unless a specific health complication arises.  Based on results of the current 
study, hormonal profiles may be better predictors of variances in total and regional body 
composition than blood lipids and may provide early indication of developing metabolic 
dysfunction.  Across the entire group, leptin and insulin were strong predictors of FM, while 
insulin and TRG were significant predictors of VATDEXA, but not VATUS.  Women typically have 
greater leptin and estradiol levels than men [17, 107].  However in the current study there was no 
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significant difference in estradiol between men and women, which has been previously reported 
in obese men [14, 23, 24].  Despite potential hormonal activity of adipose tissue, estradiol in the 
current study was not a significant predictor of variances in FM or VATUS in males, but it was a 
significant predictor of LM, RMR, and RERbike.  The relationship between estradiol, LM, and 
RMR are likely a corresponding association with greater body mass, but the relationship with 
RERbike could suggest that relatively high levels of estradiol in men, as was observed in the 
current study, may have metabolic consequences [108].  In contrast, variances in FM, VATUS, 
and RMR in women in the current study were more strongly predicted by insulin, reiterating the 
more serious implications VAT accumulation may have in women.  Previous studies have 
associated VAT with increased cortisol levels [26, 27], however, cortisol was not a strong 
predictor of VATUS or VATDEXA in the current study.  Further, there were no significant 
predictors of VATUS in men, stressing the importance of assessing VAT when evaluating 
metabolic health.  Interestingly, HDL was a negative predictor of LM, metabolic rate, and 
RERrest in the group overall.  While further investigation into this relationship is required, these 
results may implicate HDL as a blood marker of non-traditional measures of metabolic health.  
High leptin and estradiol levels in men may be an indication of excess fat accumulation and an 
early sign of metabolic dysregulation.  In women, high insulin is likely a strong predictor of 
greater VAT accumulation and its associated risks.  Evaluation of hormonal profiles, in addition 
to blood lipid markers, may be valuable in the early identification and treatment of metabolic 
health.   
Limitations exist in all studies.  Exercise is known to be an important factor in metabolic 
health and weight regulation, typically improving health status.  Although individuals were asked 
about their exercise habits, individuals were recruited for the current study based on health 
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status, not exercise habits.  However, regardless of exercise status, all individuals were still 
considered overweight or obese based on BMI and %fat.  Further, all individuals had maintained 
their weight within 4.5 kg for at least three months prior to testing, suggesting that despite 
potential benefits of exercise, other mechanisms were preventing these individuals from reaching 
a normal weight.  Results and techniques used in the current study offer a more complete picture 
of the metabolic status of these individuals.  Future exercise or dietary interventions that aim to 
decrease VAT, increase quality LM, improve fuel utilization, and restore hormonal balance may 
be effective. 
In conclusion, traditional measures of metabolic dysfunction may not give a complete 
picture of metabolic health in overweight and obese adults.  Other components of body 
composition have important associations with components of metabolic health, even in the 
presence of excess FM, and should be considered when determining metabolic health risk.  Total 
body fat may have strong associations with hormonal factors, while VAT is more closely related 
to signs of insulin resistance, especially in women.   Lean mass is generally associated with 
positive health benefits, but accounting for intramuscular fat may be an important factor when 
evaluating overweight and obese adults.  Future studies characterizing intramuscular fat and 
corresponding influences on metabolic rate and fuel utilization in obese populations should be 
explored.  Ultrasound may be a feasible option for clinical settings to evaluate VAT, improving 
the accuracy of evaluating abdominal obesity related risk and early detection of metabolic 
diseases.  Metabolic syndrome is defined by excess abdominal fat, dyslipidemia, and insulin 
resistance, but these risk factors are the result of an accumulation of factors that could be 
prevented.  Results of this study support the evaluation of hormonal profiles as a sign of 
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developing dysfunction, while assessments of fat distribution, LM, metabolic rate, and fuel 
utilization could guide interventions for preventing the development of further dysfunction. 
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TABLES 
 
Table 1:  Subject characteristics (Mean ± standard deviation [SD]) 
 Total Male Female 
N 49 23 26 
Age (yrs) 35.0 ± 8.9 37.4 ± 10.3 32.8 ± 6.9 
Height (cm) 170.7 ± 9.7* 178.1 ± 6.4 164.1 ± 7.1 
Weight (kg) 97.9 ± 17.7 102.2 ± 15.1 94.2 ± 19.3 
BMI (kg·m-2) 33.6 ± 5.2 32.1 ± 3.3 34.9 ± 6.2 
FM (kg) 39.2 ±10.8* 34.8 ± 8.8 43.1 ± 11.0 
LM (kg) 58.7 ± 12.1* 67.4 ± 8.6 51.0 ± 9.4 
LMI (kg·m-2) 20.0 ± 2.6* 21.2 ± 1.7 18.9 ± 2.9 
%fat 40.0 ± 7.3* 33.8 ± 4.8 45.5 ± 4.1 
VAT (cm) 6.0 ± 1.8 6.5 ± 1.9 5.5 ± 1.6 
RMR (kcal/day) 1813.2 ± 311.2* 2011.1 ± 259.1 1638.2 ± 242.8 
RERrest 0.9 ± 0.1 0.9 ± 0.0 0.8 ± 0.1 
RERbike 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 
TC (mg/dL) 185.5 ± 39.5 191.4 ± 35.0 179.4 ± 44.5 
LDL (mg/dL) 118.8 ± 34.3 124.3 ± 29.6 113.0 ± 38.4 
HDL (mg/dL) 44.6 ± 12.9* 39.0 ± 7.9 50.5 ± 14.5 
TRG (mg/dL) 110.7 ± 73.5* 140.7 ± 87.7 79.3 ± 35.2 
GLUC (mg/dL) 87.2 ± 22.2 92.8 ± 29.6 81.4 ± 7.0 
Insulin (uIU/mL) 9.7 ± 7.4 8.5 ± 4.9 10.9 ± 9.2 
HOMA-IR 1.2 ± 0.9 1.1 ± 0.6 1.4 ± 1.1 
Cortisol (µg/dL) 0.3 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 
Estradiol (pg/mL) 2.0 ± 0.8 1.7 ± 0.8 2.2 ± 0.8 
Leptin (ng/mL) 36.1 ± 28.9* 15.0 ± 10.9 58.1 ± 25.2 
*significant difference between males and females (p<0.05) 
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Table 2:  Risk stratification and frequencies based on BMI, %fat, and metabolic syndrome risk factors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Stratification N (%) 
BMI Overweight (25.0-29.9) 
Obese (30-34.9) 
Obese II (35-39.9) 
Obese III (≥40) 
13 (26.5%) 
14 (28.6%) 
18 (36.73%) 
4 (8.6%) 
%fat Moderate (M<25%; F<38%) 
High (M≥25%; F≥38%) 
1 (2.0%) 
48 (98.0%) 
Metabolic Syndrome 0 Risk Factors 
1 Risk Factor 
2 Risk Factors 
3 Risk Factors 
4 Risk Factors 
14 (31.1%) 
18 (40.0%) 
12 (26.7%) 
1 (2.2%) 
0 (0%) 
Additional Metabolic Risk Factors 0 Risk Factors 
1 Risk Factor 
2 Risk Factors 
3 Risk Factors 
4 Risk Factors 
5 Risk Factors 
 6 Risk Factors 
2 (4.4%) 
7 (15.6%) 
14 (31.1%) 
11 (24.4%) 
4 (8.9%) 
6 (13.3%) 
1 (2.2%) 
Note:  Metabolic syndrome defined as the presence of 3+ risk factors including: abdominal 
obesity (VAT; >7cm), elevated triglycerides (≥150 mg/dl), low HDL cholesterol (men<40 
mg/dl, women<50 mg/dl), and elevated fasting glucose (≥110 mg/dl).  Additional 
metabolic risk factors included LMI, RMR, RERrest, TC, LDL, leptin, cortisol, and HOMA-
IR, in addition to the traditional metabolic syndrome risk factors. 
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Table 3:  Stratification and frequencies based on metabolic and hormonal factors. 
 
 
Stratification N (%) 
VAT Low (< 7cm) 
Moderate (M 7-9cm; W 7-8cm) 
High (M>9 cm; W >8cm) 
 
36 (73.5%) 
10 (20.4%) 
3 (6.1%) 
Glucose Low (<70 mg/dL) 
Normal (70-110 mg/dL) 
High (≥110 mg/dL) 
 
1 (2.2%) 
42 (93.3%) 
2 (4.4%) 
Triglycerides Normal (<150 mg/dL) 
High (≥ 150 mg/dL) 
 
38 (84.4%) 
7 (15.6%) 
HDL Low (M< 40 mg/dL; W< 50 mg/dL) 
Normal (M≥40 mg/dL; W≥50 mg/dL) 
 
25 (55.6%) 
20 (44.4%) 
LMI Low (<10%) 
Normal (10th – 90th %) 
High >90% 
>97% 
 
0 (0%) 
33 (67.3%) 
11 (22.4%) 
5 (10.2%) 
RMR Low (<125.6 kcal/d) 
Normal (±125.6 kcal/d) 
High (>125.6 kcal/d) 
 
22 (44.9%) 
24 (49.0%) 
3 (6.1%) 
RERrest Low (<0.82) 
Normal (0.85±0.03) 
High (>0.88) 
 
13 (26.5%) 
28 (57.1%) 
8 (16.3%) 
Total Cholesterol Low (<100 mg/dL) 
Normal (100-199 mg/dL) 
High (>200 mg/dL) 
 
4 (8.2%) 
30 (61.2%) 
15 (30.6%) 
LDL Normal (<100 mg/dL) 
Above normal (100-160 mg/dL) 
High (>160 mg/dL) 
 
13 (28.9%) 
26 (57.8%) 
6 (13.3%) 
HOMA-IR Normal (≤2.5) 
High (>2.5) 
 
44 (97.8%) 
1 (2.2%) 
Leptin Low (<10th percentile) 
Normal (10th – 90th percentile) 
High (>90th percentile) 
 
0 (0.0%) 
14 (31.1%) 
31 (68.9%) 
Estradiol Low (<1.35 pg/mL) 
Normal (1.35-2.97 pg/mL) 
High (>2.97 pg/mL) 
 
11 (22.4%) 
35 (71.4%) 
3 (6.1%) 
Cortisol Low 
Normal 
High 
 
7 (14.3%) 
42 (85.7%) 
0 (0%) 
Note:  VAT, glucose, triglycerides, and HDL are considered risk factors for metabolic syndrome.  
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FIGURES  
Initial Electronic Correspondence 
(n=114) 
Excluded (n=50) 
 Did not meet inclusion/exclusion criteria (n=34) 
 Did not respond to initial contact (n=16) 
In-Person Enrollment Visit 
(n=64) 
Excluded (n=8) 
 taking dietary supplements (n=1) 
 >10 lbs of weight change in the last three months (n=2) 
 unable to meet time requirements (n=1)  
 substantial dietary changes in the last three months (n=1) 
 did not meet a number of inclusion/exclusion criteria (n=1) 
 inconsistent medications (n=1) 
 taking multiple medications (n=1) 
Enrolled 
(n=56) 
Excluded (n=7) 
 withdrew for personal reasons (n=4) 
 no explanation for withdraw (n=3) 
Tested and Analyzed 
(n=49; men=23, women=26) 
 
Figure 1: CON SORT flow diagram 
Figure 1:  CONSORT flow diagram of subject recruitment and enrollment for study participation and 
analysis. 
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Figure 2:  Experimental timeline. 
  
VISIT 1 VISIT 2 VISIT 3 
2 Week Run-In 0-72 Hours 
Visit 1: Enrollment 
 Informed consent 
 Health history questionnaire 
 Age, height, weight, BMI 
 4-day dietary intake analysis 
and interpretation 
Visit 2: Testing 
 Resting metabolic rate 
 Body composition 
 Fasted blood draw 
 Saliva Sample 
Visit 3: Testing 
 Steady-state cardiorespiratory 
assessment 
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Figure 3: Measurements of VAT 
Figure 3:  Measurements of VAT.  (A) Abdominal US scan; VATUS thickness was measured 
between the interior border of the rectus abdominis and the posterior wall of the aorta.  (B) 
Android region-of-interest set by DEXA software to quantify VATDEXA.  Parameters of the 
region span from the top of the iliac crest to a height 20% of the distance from the top of the iliac 
crest to the base of the skull to the width of the torso. 
 
  
 
A B 
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Figure 4:  Resting metabolic rate ventilated canopy with indirect calorimetry.  
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Figure 5: Five females with LMI>97th percentile compared with the female group average 
Figure 5:  Five females with LMI>97th percentile based on age and race, (represented by the colored dots) compared with the female 
group average (represented by the blue bars).  Of the five women considered to have above average LM, all were considered to be in 
the obese II or obese III categories and had a %fat>40%; two were considered to have moderate (7-8cm) and high VAT (>8cm).  All 
five women had normal metabolic rates (±125.6 kcal/d from predicted); two had an RER>0.88, potentially indicating increased 
reliance on carbohydrate at rest; two had an RER<0.82, potentially indicating greater reliance on fat at rest; one had an RER=0.86, 
potentially indicating equal contribution of carbohydrate and fat at rest.  All women had normal TC, TRG, and GLUC while four of 
the five had normal LDL.  
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 Figure 6: Individual RMR and RERrest value 
Figure 6:  Individual RMR and RERrest values.  Resting metabolic rate is represented as the 
differences between predicted and measured.  Respiratory exchange ratio values are represented 
as the difference between measured and 0.85 a.u.  High and low cutoffs were set at SEM for RMR 
and RERrest respectively. 
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